Jose Luis ALONSO ROMERO

Gabaldó Barrios X, Sarabia Meseguer MD, Marín Vera M, Sánchez Bermúdez AI, Macías Cerrolaza JA, Sánchez Henarejos P, Zafra Poves M, García Hernández MR, Cuevas Tortosa E, Aliaga Baño Á, Castillo Guardiola V, Martínez Hernández P, Tovar Zapata I, Martínez Barba E, Ayala de la Peña F, Alonso Romero JL, Noguera Velasco JA, Ruiz Espejo F. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers. Fam Cancer. 2017 Oct;16(4):477-489. doi: 10.1007/s10689-017-9985-x. PubMed PMID: 28477318.

AÑO: 2017; IF: 1.943

28477318

García-Vizcaíno EM, Liarte S, Alonso-Romero JL, Nicolás FJ. Sirt1 interaction with active Smad2 modulates transforming growth factor-β regulated transcription. Cell Commun Signal. 2017 Nov 29;15(1):50. doi: 10.1186/s12964-017-0205-y. PubMed PMID: 29187201; PubMed Central PMCID: PMC5706420.

AÑO: 2017; IF: 5.324

29187201

Marín Hernández C, Piñero Madrona A, Gil Vázquez PJ, Galindo Fernández PJ, Ruiz Merino G, Alonso Romero JL, Parrilla Paricio P. Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy. Clin Transl Oncol. 2018 Apr;20(4):476-483. doi: 10.1007/s12094-017-1732-0. Epub 2017 Aug 7. PubMed PMID: 28785911.

AÑO: 2018; IF: 2.441

28785911

Sánchez-Bermúdez AI, Sarabia-Meseguer MD, García-Aliaga Á, Marín-Vera M, Macías-Cerrolaza JA, Henaréjos PS, Guardiola-Castillo V, Peña FA, Alonso-Romero JL, Noguera-Velasco JA, Ruiz-Espejo F. Mutational analysis of RAD51C and RAD51D genes in hereditary breast and ovarian cancer families from Murcia (southeastern Spain). Eur J Med Genet. 2018 Jun;61(6):355-361. doi: 10.1016/j.ejmg.2018.01.015. Epub 2018 Feb 2. PubMed PMID: 29409816.

AÑO: 2018; IF: 2.022

29409816

Liarte S, Alonso-Romero JL, Nicolás FJ. SIRT1 and Estrogen Signaling Cooperation for Breast Cancer Onset and Progression. Front Endocrinol (Lausanne). 2018 Sep 27;9:552. doi: 10.3389/fendo.2018.00552. eCollection 2018. Review. PubMed PMID: 30319540; PubMed Central PMCID: PMC6170604.

AÑO: 2018; IF: 3.634

30319540